ALK-Abello A/S
CSE:ALK B

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
CSE:ALK B
Watchlist
Price: 182 DKK 2.3% Market Closed
Market Cap: 36.9B DKK

Relative Value

The Relative Value of one ALK B stock under the Base Case scenario is 223.26 DKK. Compared to the current market price of 182 DKK, ALK-Abello A/S is Undervalued by 18%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALK B Relative Value
Base Case
223.26 DKK
Undervaluation 18%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
30
vs Industry
23
Median 3Y
6
Median 5Y
6.1
Industry
2.5
Forward
6.3
vs History
79
vs Industry
11
Median 3Y
51.2
Median 5Y
57.1
Industry
21.3
Forward
35.7
vs History
76
vs Industry
16
Median 3Y
41.3
Median 5Y
46.5
Industry
16.7
vs History
23
vs Industry
3
Median 3Y
81.8
Median 5Y
72.4
Industry
24.7
vs History
39
vs Industry
12
Median 3Y
6.3
Median 5Y
6.6
Industry
2.1
vs History
31
vs Industry
22
Median 3Y
6
Median 5Y
6.2
Industry
2.6
Forward
6.3
vs History
34
vs Industry
24
Median 3Y
9.5
Median 5Y
9.9
Industry
5.1
vs History
63
vs Industry
16
Median 3Y
28.2
Median 5Y
29.4
Industry
12.8
Forward
20.9
vs History
71
vs Industry
16
Median 3Y
37.6
Median 5Y
40.4
Industry
16.3
Forward
25.2
vs History
76
vs Industry
17
Median 3Y
42.3
Median 5Y
47
Industry
14.9
vs History
0
vs Industry
6
Median 3Y
173.6
Median 5Y
154.1
Industry
18.2
vs History
28
vs Industry
18
Median 3Y
4.5
Median 5Y
4.7
Industry
1.9

Multiples Across Competitors

ALK B Competitors Multiples
ALK-Abello A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
ALK-Abello A/S
CSE:ALK B
40.3B DKK 7.1 43 26.5 32.3
US
Eli Lilly and Co
NYSE:LLY
714.3B USD 14.6 64.3 34.6 37.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
371.8B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 6.8 19.8 13.7 15.7
CH
Roche Holding AG
SIX:ROG
209.9B CHF 3.5 25.4 9.5 11.1
CH
Novartis AG
SIX:NOVN
187B CHF 4.3 17.8 10.5 14.1
UK
AstraZeneca PLC
LSE:AZN
164.9B GBP 4.1 28.8 131 197.5
US
Merck & Co Inc
NYSE:MRK
192.9B USD 3 11.1 8.3 10
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
133B USD 2.1 16.9 7.3 10.3
P/E Multiple
Earnings Growth PEG
DK
ALK-Abello A/S
CSE:ALK B
Average P/E: 27.1
43
23%
1.9
US
Eli Lilly and Co
NYSE:LLY
64.3
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.8
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.4
32%
0.8
CH
Novartis AG
SIX:NOVN
17.8
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.8
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.1
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.9
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average EV/EBITDA: 396.5
26.5
21%
1.3
US
Eli Lilly and Co
NYSE:LLY
34.6
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.5
5%
1.9
CH
Novartis AG
SIX:NOVN
10.5
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.3
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average EV/EBIT: 1 700.3
32.3
23%
1.4
US
Eli Lilly and Co
NYSE:LLY
37.8
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.9
CH
Novartis AG
SIX:NOVN
14.1
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.5
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1